NCCN Guidelines and Compendium Updated
Flash Update Sent May 31, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers. These NCCN Guidelines® are currently available as Version 1.2012.
- The Discussion section has been updated to reflect the changes in the algorithm.
*For your reference, the announcement of the previous update (Version 1.2012) to the NCCN Guidelines for Acute Myeloid Leukemia, distributed on April 17, 2012, is included below:
NCCN has published updates to the NCCN Guidelines for Acute Myeloid Leukemia. These NCCN Guidelines are currently available as Version 1.2012.
- Diagnostic workup modified to reflect that multidisciplinary diagnostic studies should be performed according to WHO 2008 classification to establish the diagnosis of AML/MDS versus lymphoblastic leukemia/lymphomas.
- Lumbar puncture added as a consideration after treatment with induction for patients with high-risk acute promyelocytic leukemia (APL).
- Patients with acute myeloid leukemia (AML) under the age of 60 years, post-remission therapy for better-risk cytogenetics or molecular abnormalities was modified by the change in dose of cytarabine from 1.5-3 g/m2 to 3 g/m2. Maintenance chemotherapy removed as a treatment option after high-dose cytarabine.
- A footnote was added to post-remission therapy with cytarabine for better-risk cytogenetics: "Alternate dosing of cytarabine for postremission therapy has been reported (see Discussion). Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:1027-1036."
- A footnote was added for patients with AML over the age of 60 years, "There is a web-based scoring tool available to evaluate the probability of CR and early death after intensive induction therapy in elderly patients with AML: Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukemia: a web-based application for prediction of outcomes. Lancet 2010;376:2000-2008."
- Patients with AML over the age of 60 years, the following treatment options changed from category 2B recommendations to category 2A recommendations: low intensity therapy (5-azacytidine, decitabine).
- Patients with AML over the age of 60 years and significant comorbidities, the following treatment options added as category 2A recommendations: low intensity therapy (5-azacytidine, decitabine, subcutaneous cytarabine).
- Clofarabine + cytarabine + GCSF added as a salvage chemotherapy regimen option with a category 2A recommendation.
NCCN has published new NCCN Guidelines for Patients™: Non-Small Cell Lung Cancer. These NCCN Guidelines for Patients™ are currently available as Version 1.2012.
The NCCN Guidelines for Patients™: Non-Small Cell Lung Cancer are a high-quality resource for patients in the process of treatment planning. Lung cancer is common and the leading cause of cancer death in the United States. National Comprehensive Cancer Network® (NCCN®) aims to help patients and their families learn what the best practice for this serious disease is. These Patient Guidelines include NCCN's most recent treatment recommendations for each stage of lung cancer as well as descriptions of the tests and treatments. These Patient Guidelines were developed according to plain language principles and include definitions of medical terms to improve health literacy. The NCCN Guidelines for Patients are available free of charge at NCCN.com and NCCN.org.
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.